PMC:7417114 / 45379-45909
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T236 | 152-158 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T237 | 394-400 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T535 | 52-55 | http://purl.obolibrary.org/obo/UBERON_0001013 | denotes | fat |
| T536 | 152-158 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T537 | 219-220 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T538 | 394-400 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T400 | 302-308 | Chemical | denotes | flavin | http://purl.obolibrary.org/obo/CHEBI_30527 |
| T401 | 337-353 | Chemical | denotes | CYP3A4 inhibitor | http://purl.obolibrary.org/obo/CHEBI_86501 |
| T402 | 344-353 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T403 | 379-390 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
| T404 | 473-483 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1484 | 285-291 | Gene | denotes | CYP3A4 | Gene:1576 |
| 1485 | 293-300 | Gene | denotes | CYP2C19 | Gene:1557 |
| 1486 | 302-335 | Gene | denotes | flavin-containing monooxygenase 3 | Gene:2328 |
| 1487 | 337-343 | Gene | denotes | CYP3A4 | Gene:1576 |
| 1488 | 467-472 | Gene | denotes | CYP3A | Gene:1576 |
| 1556 | 444-452 | Species | denotes | patients | Tax:9606 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T359 | 0-20 | Sentence | denotes | Fedratinib (Inrebic) |
| T360 | 21-83 | Sentence | denotes | (Celgene) Not affected by high fat breakfast; 400mg oral dose: |
| T361 | 84-121 | Sentence | denotes | Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL |
| T362 | 122-128 | Sentence | denotes | (210); |
| T363 | 129-259 | Sentence | denotes | rapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner; |
| T364 | 260-336 | Sentence | denotes | Vd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3; |
| T365 | 337-516 | Sentence | denotes | CYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment; |
| T366 | 517-530 | Sentence | denotes | > 92% binding |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32778962-27136912-84130718 | 123-126 | 27136912 | denotes | 210 |